brian caulkins

Two strikeouts in the 4th, Gabe Nard has retired all 6 batters he's faced. E-4, FSU 1, UNF 0

😎

This week in the national rankings 📈

The series was won with a 12-11 victory on Saturday, beginning with a four-run first inning. Three bases-loaded walks in the seventh added insurance runs before Gabe Nard closed it out for his first save.

Gabe Nard gets a K looking to strand the tying run on third. FSU wins the series. FINAL: FSU 12, Duke 11

Big news. Target price $1 within 12 months NWBO😍 markets.ft.com/data/announce/…

$NWBO Fighting Cancer With Vaccines: A Bold New Partnership youtube.com/watch?v=NObKyJ…

$TNXP Any one can get a better deal than @TonixPharma insiders who rewarded themselves options yesterday if you buy today! But @elonmusk @X shadow banning my account, so it's doubtful this good news can reach many potential investors. But gl & congrats if you did see this! 🚀🚀🚀

BOXABL achieves reduction of inspections to 25% from California for Casita Studio product line as proposed merger with FG Merger II Corp (NASDAQ: FGMC) makes progress. FGMC News: - FGMC is currently trading on Nasdaq, FGMC will be the surviving entity following the proposed merger's closing. The combined company will then be renamed BOXABL Inc., with the anticipated ticker $BXBL. - Investors holding $FGMC shares at the closing will automatically convert to $BXBL upon closing. View FGMC on Yahoo Finance finance.yahoo.com/quote/FGMC/ The merger could provide, what we believe, is significant access to capital for BOXABL for its business operations and growth initiatives. Review the latest filings sec.gov/edgar/browse/?… Thank you for your support!

#google_vignette" target="_blank" rel="nofollow noopener">fox13now.com/news/local-new…

We’re continuing deliveries and advancing additional state modular approvals. We’ve also secured our California Commercial Modular License, a significant milestone that follows the signing of a contract with an industry leader. BOXABL recently announced plans for a proposed SPAC merger with FG Merger II Corp. (“FGMC”). View FGMC on Yahoo Finance finance.yahoo.com/quote/FGMC/ FGMC News: - Investors holding $FGMC shares at the closing will automatically convert to $BXBL upon closing. - FGMC is currently trading on Nasdaq, FGMC will be the surviving entity following the proposed merger's closing. The combined company will then be renamed BOXABL Inc., with the anticipated ticker $BXBL. The merger could provide, what we believe, is significant capital to BOXABL for its business operations and growth initiatives. Review the latest filings: sec.gov/edgar/browse/?… Thank you for your support!

Some of the best in the country wear the Garnet and Gold, including the No. 1⃣-ranked first baseman.

With the start of the Winter Olympics, how would we fare on snow or ice? ❄️

I love this pitching staff. When healthy, Bryson Moore has proven himself and Payton Manca is a big breakout candidate. And bullpen has three proven bullpen aces in Stokes, Purcell, and Nard. Excited for the Noles.

$NWBO Great news here. This is proof of how legitimate #DCVax is becoming. All things are moving in our direction. Northwest Bio is the only named company in the article prnewswire.com/news-releases/…

🧨 Short Circuit in Penny Stock Land: How $NWBO Built a Quiet Exit Ramp From the OTC Trap Before anyone pins this story to a single day, the boundary gets drawn once and cleanly. What is known is boring and checkable. NWBO has an existing London Stock Exchange line under ticker 0K95 with ISIN US66737P6007, and the LSE’s instrument page shows an issue date of 24 January 2018. On 19 January 2026, the UK’s new public offers and admissions regime takes effect, and the FCA’s final rules in PS25/9 raise the “further issuance” prospectus trigger for transferable securities already admitted to trading from 20% to 75%. NWBO’s SEC filings show two specific share-count snapshots: in its 10-Q, the company states that as of November 13, 2025, it had 1,540,682,082 common shares outstanding. In its DEF 14A, it states that as of the close of business on November 14, 2025, it had 1,528,682,082 common shares outstanding and 818,142 preferred shares outstanding. Shareholders approved increasing authorized common shares from 1.7 billion to 2.6 billion, and the company filed a Certificate of Amendment on December 30, 2025 to effect that increase. NWBO’s filings also set out the Series C conversion mechanics: 10,000,000 Series C shares authorized, and each Series C share convertible into 25 common shares once conditions are met—implying up to 250 million common-equivalent shares. What is possible follows from those facts. NWBO now has more ways to compress the time between “plan” and “execution,” and that weakens the most profitable OTC short thesis—the thesis that lives on delays and visible countdowns. There’s a financial weather system that forms over the OTC market. It isn’t about good companies versus bad companies. It’s about what happens when a stock trades in thin liquidity, where big institutional buyers rarely show up, where financing is survival, and where the people who do show up every day can learn to steer the tape. Northwest Biotherapeutics has lived under that weather system for years. Some investors see a slow-motion breakthrough story. Others see a slow-motion implosion. But both camps often miss the real plot. On OTC, the most profitable trade is rarely “the science is fake.” It’s something simpler and more brutal. It’s “they won’t finance cleanly in time.” And if that’s the bet, the counter-bet isn’t an argument. It’s a clock hack. This piece explains how NWBO can reduce the market’s ability to trade its deadlines—through lawful disclosure timing, regulatory tempo, institutional access, market plumbing, and one sleeper asset most traders ignored: the London Stock Exchange rail called 0K95. ⸻ 🏚️ The OTC Isn’t a Lower Exchange. It’s a Different Machine. The OTC market is often described like it’s just a cheaper, lower version of a major exchange. It isn’t. It’s a different machine. A major exchange is a crowded city. Even when sentiment turns sour, there are still pedestrians. There’s depth. Big funds can enter and exit without detonating the price because enough participants absorb slow, steady flows. The market has mass. OTC is a rural road at night. A few cars pass. Sometimes none. When one driver taps the brakes, the whole road reacts. That difference isn’t cosmetic. It changes everything. OTC tends to mean thinner displayed depth, wider spreads, fewer persistent buyers, and far less automatic demand from institutions and index flows. Thin marginal demand makes price easier to steer, and steerability is what turns a financing calendar into a trade. That is the trap. ⸻ 🧠 The Real Short Bet: Time, Not Truth. Short selling is straightforward: borrow shares, sell them, hope to buy them back later lower, return them, keep the difference. The risk is unlimited on the upside, which is why successful shorts don’t just bet on direction. They bet on structure. In OTC biotech, the durable bet isn’t “the drug won’t work.” It’s “the company won’t survive long enough for the drug to matter.” That survival risk collapses into three variables: Cash runway. Financing timing. Regulatory uncertainty. So the thesis becomes temporal: They can’t finance cleanly before the next deadline. That’s why OTC stocks can behave in a way that drives long investors insane. Good news doesn’t re-rate the stock; it gets sold into. Because the market interprets good news as a financing window. If the company still looks like it needs money, a rally is treated as supply. Not because the news was fake. Because the clock is still on the short seller’s side. To beat a time trade, the company has to reduce the market’s ability to trade the countdown. ⸻ 🧾 The Shares: The Math That Turns Time Into a Weapon — The One-Third Partner Slot This is what the “Rule of Thirds” idea means in plain English. It isn’t a code. It’s a deal shape. In biopharma, there is a common middle ground between “no partner” and “buy the whole company.” A large company takes a meaningful minority stake—large enough to align incentives and justify serious capital, small enough to avoid control. That ownership band often sits in the one-third neighborhood because it’s a natural balance point: big enough to matter, not big enough to become a takeover. That’s the one-third partner slot. Now the numbers that make this more than vibes: • NWBO’s 10-Q states 1,540,682,082 common shares outstanding as of Nov 13, 2025. • NWBO’s DEF 14A states 1,528,682,082 common shares outstanding as of the Nov 14, 2025 record date. • Authorized common shares increased from 1.7B to 2.6B, effective via a Dec 30, 2025 Certificate of Amendment. Authorized shares are not dilution. They are capacity—legal inventory. Capacity matters because it reduces delay. Delay is the oxygen of the time-based short thesis. Now add the instrument lane that sits quietly in filings: Series C Convertible Preferred. NWBO disclosures describe Series C shares being convertible into 25 common shares per Series C share, and the designation of 10,000,000 Series C shares implies up to 250 million common-equivalents. Put the geometry together: • a 900 million increase in authorized common capacity • a preferred conversion lane of up to 250 million common-equivalents • a common base around 1.53–1.54 billion outstanding at the time This is why the one-third partner slot keeps showing up in serious thinking. The cap table now enables a large minority stake to be structured through a combination of preferred conversion capacity and common issuance headroom, without requiring an outright acquisition and without forcing the company into a slow, tradeable survival raise. That doesn’t say a partner exists. It says the company is now built to take one. ⸻ 🎛️ Path Control: How Thin Liquidity Turns Into a Price Narrative In a deep market, repetition is expensive. In a thin market, small persistent pressure can shape the path. The tape teaches this lesson through repetition: rallies stall early, key levels fail, quiet-day downdrafts land harder than they should, and bids vanish when volatility spikes. Buyers learn not to chase. Holders learn to sell sooner. Once that behavior takes hold, it becomes cheaper to keep it in place. That’s why the company doesn’t merely need good news. It needs an execution architecture that interrupts what the market has learned—by collapsing the reaction window. ⸻ 🏛️ Institutions: The Missing Demand Layer That Changes Everything OTC suppresses institutional participation not because institutions are sentimental, but because they are constrained. Many funds can’t buy, won’t buy, or can’t size positions rationally in thin OTC names. A second venue is not just a second price. It’s a second compliance reality. Institutional capital doesn’t arrive because a company is interesting. It arrives because a company is financeable: clean enough, liquid enough, and executable enough to defend in committee. That’s why the 0K95 rail matters even before it becomes liquid. It widens the battlefield. It creates a second place where price can print under a recognized exchange environment. And it is thin today. That’s a description, not an insult. Some market data views show periods with no trades, while others show sporadic bursts of volume—either way, it is not a deep, continuously traded line. Thinness doesn’t negate it. Thinness is exactly why a credible external print can matter disproportionately if attention and demand arrive at the same time. ⸻ 🕳️ Scenario Analysis: The Swapbook Amplifier This section describes a general mechanism; there is no public data demonstrating a specific large swapbook in NWBO. A total return swap is a contract that gives a fund economic exposure to a stock without owning it outright. The counterparty—usually a prime broker—hedges by buying or shorting the real shares into the market. The world learned this in Archegos. The SEC’s complaint states Archegos used swaps “to limit the visibility” of its aggregate holdings and shifted from cash equity to synthetic exposure via swaps as it approached the 5% reporting threshold. Congressional research notes Archegos reportedly never filed a 13D despite large economic exposure via total return swaps. The takeaway is structural: economic exposure can be larger than what is visible on a short-interest report, and dealer hedging can amplify moves when the tape flips. In thin names, that amplification doesn’t glide. It stair-steps. ⸻ 🤫 The Quiet Weapon: UK MAR Delayed Disclosure Silence is not emptiness. In regulated markets, silence can be a tool. UK MAR—the UK Market Abuse Regulation—is the UK’s market integrity and disclosure rulebook. It governs inside information: material nonpublic information that would likely move a stock if investors knew it. UK MAR requires prompt disclosure in general. But it also recognizes that some processes are materially important but operationally incomplete. Disclose too early and negotiations can collapse, unfinished regulatory processes can be distorted, and the public can be misled into treating intermediate states as final. So UK MAR includes a lawful mechanism for delayed disclosure under strict conditions: Immediate disclosure would prejudice legitimate interests. Delay would not be likely to mislead the public. Confidentiality can be maintained. In a time-based short regime, the effect is surgical. Delayed disclosure forces shorts to trade probabilities instead of timing. Inside a lawful quiet window, a company can prepare contingent financing terms, align partners under nondisclosure agreements, stage documentation, and build execution capacity so the announcement is not a scramble. That is how the reaction window collapses: preparation happens while the countdown is invisible, and execution happens when certainty arrives. ⸻ 🌉 The Sleeper Rail in London: 0K95 and the January Turn NWBO has a London Stock Exchange trading line under ticker 0K95, and the LSE’s own page lists an issue date of 24 January 2018 and ISIN US66737P6007. The January shift is the real turn. The rail existed. What changes in January is the operating environment: the new UK public offers and admissions regime takes effect on 19 January 2026, replacing the inherited UK Prospectus Regulation with the FCA’s new rulebook-led framework. Activation is not a press release. Activation is a market event. It happens when real order flow runs through the London line, when brokers and market makers quote it with intent, and when London becomes the first venue to establish a reference price during a window when the US tape is offline. Once it’s used, path control becomes containment. Containment is more expensive. ⸻ 🏦 Why SETSqx Matters: Auctions Can Jump Where Continuous Trading Drifts The London Stock Exchange’s SETSqx model is built for less liquid securities. The LSE describes it as combining a periodic electronic auction book with quote-driven market making. Continuous trading can bleed buying pressure gradually. Auctions can bunch demand and clear it at a single equilibrium price. When demand overwhelms supply at the clearing event, the price steps. London doesn’t need to become the primary market. It only needs to print a credible reference price during a moment when demand is concentrated and supply is thin. ⸻ 📜 POATRs and PS25/9: The January Rule Change That Cuts Time Taxes January 2026 matters because the UK’s capital-markets framework changes in a real way. The new regime takes effect 19 January 2026, and the FCA’s policy statement PS25/9 spells out a key change: increasing the threshold at which a prospectus is required for a further issuance of transferable securities from 20% to 75% of those same securities already admitted to trading. That does not guarantee a financing. It reduces the slow prospectus bottleneck that forces financings to telegraph themselves and creates a long pre-financing window that shorts can front-run. Shorten the window and the time trade loses oxygen. ⸻ 🧬 Big Pharma: The Nonlinear Catalyst that Makes the Setup Financeable What follows is scenario analysis, not a description of any announced transaction. Big Pharma doesn’t finance stories. Big Pharma finances systems. A major partner can remove solvency fragility in one move. It can validate diligence. It can improve financing terms. It can change the pricing regime from survival to optionality. And the minority-stake deal shape described earlier is not theoretical. In 2019, Gilead and Galapagos announced a collaboration that included warrants allowing Gilead to increase ownership up to 29.9%, alongside a 10-year standstill restricting Gilead from seeking to acquire Galapagos or increasing its stake beyond that level. That’s the template: meaningful ownership without control, paired with deep strategic access. ⸻ 🧹 The 8-K: Not the Hinge, the Housekeeping The structural story is bigger than one filing. But the filing matters in the way boring things matter in capital markets: it trims an overhang. NWBO’s January 15, 2026 Form 8-K states that the company entered into a settlement agreement regarding Delaware Court of Chancery litigation relating to 2020 option awards, and that under the terms of the settlement the company’s insurance carriers will pay $2.25 million to the company and 17% of the challenged 2020 options will be cancelled, among other terms. That isn’t a London prerequisite. It is friction reduction. ⸻ ⚙️ Settlement Discipline: The Strong Claim Without Fairy Tales Settlement discipline is not a guaranteed squeeze button. The strong claim is simpler: settlement culture changes the cost curve. For instance, stricter buy-in practices or tighter stock-loan terms can raise the ongoing cost of maintaining shorts—higher borrow rates, reduced availability, recalls, and less tolerance for settlement mess in the prime broker’s own book. None of this guarantees a squeeze. It raises cost and risk at the exact moment a time-based short thesis depends on cheap persistence. ⸻ 🗓️ The Holiday Window: Asymmetry that Can Matter The holiday window is a calendar asymmetry. For example, when U.S. markets are closed for Martin Luther King Jr. Day while London is open, the U.S. tape can’t respond intraday, but London can still print. If a real catalyst coincides with that kind of window, first-mover price discovery can land in London before the U.S. market has a chance to shape the tape. That asymmetry can break rhythm. In thin names, rhythm is half the trade. ⸻ ⚠️ What Forces Shorts to Cover: Risk Systems, Not Theater Short squeezes don’t happen because the internet gets angry. They happen because risk systems enforce limits. Price rises. Shorts take mark-to-market losses. Margin requirements rise. Some shorts cover. Covering pushes price higher. More shorts hit limits. The loop reinforces. ⸻ 🔚 The Master Synthesis: Tempo vs Time The OTC regime makes time tradeable. Shorts bet on the clock. NWBO’s escape architecture attacks that thesis by attacking its fuel: • POATRs/PS25/9 reduces a key prospectus time-tax for further issuances from 20% to 75% in the relevant context, shrinking pre-financing windows. • UK MAR delayed disclosure enables lawful preparation under strict conditions, so execution can be faster once certainty arrives. • 0K95 provides a real London rail, even if thin today, operating under SETSqx auction mechanics that can print stepwise references. • Share capacity + Series C terms make a serious strategic partner deal shape mechanically feasible. • Big Pharma precedent shows the large minority-stake template is real, not exotic. • Swaps explain how visible short interest can understate exposure and why reversals can amplify under dealer hedging. • 8-K housekeeping trims friction and removes a governance overhang. ⚖️ Disclaimer: This is for informational and educational purposes only and is not investment advice.

$NWBO

#dcvax $nwbo #gbm

@Prohumanistx @investseekers If by R&D champ you mean they bought the company that invented SNAC then you are correct. Emisphere !

@investseekers Yes they are the r&d Champion

$NVO explains how it cracked a 100-year-old medical problem: turning injectable biologic drugs into a pill. The company details how biologics are normally broken down like food, why earlier attempts failed, and how Novo combined protein engineering with the carrier molecule SNAC to create oral semaglutide, the world’s first oral GLP-1, launched for diabetes in 2019 and approved for weight management in the U.S. in 2025. It’s an interesting read. Read it here: novonordisk.com/disease-areas/… #StocksInFocus #investing

Ummmm….they bought Emisphere . The ticker was EMIS. EMIS developed SNAC. Research it, NVO didn’t crack anything.